Gilead Sciences, Inc. (NASDAQ:GILD) has revealed encouraging results from its ASCENT-03 clinical trial, showcasing a major ...

Gilead Sciences (NASDAQ:GILD) announced Friday that its antibody-drug conjugate Trodelvy reached the main goal compared to ...

Gilead (GILD) announced topline results from the Phase 3 ASCENT-03 study of Trodelvy. The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful ...

After meeting the mark alongside Keytruda in PD-L1-positive breast cancer earlier this year, Gilead Sciences' antibody-drug ...

Gilead Sciences (NasdaqGS:GILD) recently announced positive results from its ASCENT-03 study, leading to a significant role ...

Gilead Sciences, Inc. (GILD) announced on Monday that its late-stage study showed a combination of its drug Trodelvy with Merck's (MRK) immuno-oncology agent Keytruda significantly improved ...

Gilead's Trodelvy shows significant improvement in progression-free survival for metastatic triple-negative breast cancer ...

Trodelvy (sacituzumab govitecan-hziy) is a prescription drug used to treat certain kinds of breast cancer. This drug can interact with some other medications. For example, Trodelvy can interact ...

Trodelvy + Keytruda improved progression-free survival over chemo + Keytruda in PD-L1+ metastatic TNBC. No new safety signals reported in ASCENT-04; overall survival trends will be tracked with mo ...

The results of Gilead's much-anticipated TROPiCS-02 study of Trodelvy are in, and while the company says top-line data are positive, its guarded stance has rung some alarm bells.

Trodelvy’s combination with Merck & Co.’s Keytruda was better than Keytruda and chemotherapy at prolonging the time before cancer returns or death in patients with previously untreated ...